Patent · US Active

RNAi inhibition of alpha-ENaC expression

US7943592B2 · kind B2 · utility

17Cited by

16References

20Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Gino Van Heeke · Gainesville, US
Emma Hickman · Horsham, GB
Henry Luke Danahay · Horsham, GB
Pamela Tan · Kulmbach, DE
Anke Geick · Bayreuth, DE
Hans-Peter Vornlocher · Bayreuth, DE

Key dates

Filing date	Apr 30, 2010
Grant date	May 17, 2011
Priority date	—
Expiry date	Apr 30, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.